ID Biomedical Gets U.S. Flu Vaccine Deal  MONTREAL (Reuters) - ID Biomedical Corp. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=IDB.TO target=/stocks/quickinfo/fullquote"&gt;IDB.TO&lt;/A&gt; &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=IDBE.O target=/stocks/quickinfo/fullquote"&gt;IDBE.O&lt;/A&gt;  signed a distribution deal for its Fluviral drug that could  reap sales of up to \$2.5 billion over a decade and help U.S.  authorities ease a vaccine shortage as early as next year, it  said on Monday.